Maytansinoid B

• Description :

  Maytansinoid B is a kind of ADC Cytotoxin. Maytansinoid B can be used to conjugates with antibodies to form antibody-drug conjugates (ADCs) . Maytansinoids are known as antimitotic agents, binding to tubulin and inhibiting microtubule assembly. Maytansinoids induces G2/M arrest in the cell cycle to induce apoptosis[1][2].

• CAS Number :

  [1628543-40-7]

• UNSPSC :

  12352203

• Target :

  ADC Payload

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/maytansinoid-b.html

• Purity :

  99.06

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N(C)[C@@H](C)C(O[C@H]([C@@]1(C)[C@@H](O1)[C@@H]2C)CC(N(C)C3=C(Cl)C(OC)=CC(C/C(C)=C/C=C/[C@@H](OC)[C@]4(O)NC(O[C@H]2C4)=O)=C3)=O)=O)CCNC

• Molecular Formula :

  C36H51ClN4O10

• Molecular Weight :

  735.26

• References & Citations :

  [1]Blanc V, et al. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011 Oct 15;17 (20) :6448-58. |[2]Andreev Julian, et al. Bispecific antigen binding molecules that bind HER2, and methods of use thereof: World Intellectual Property Organization, WO2021174113. 2021-09-02.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported